Related Experiment Videos
Molecular genetics of malignant insulinoma
K Pavelic1, R Hrascan, S Kapitanovic
1Department of Molecular Medicine, Ruder Boskovic Institute, Zagreb, Croatia.
Abstract:
Malignant insulinoma is an rare form of cancer with poor prognosis and a reported 5-year survival of 35%. Relatively little is known about the etiology of this disease or of the oncogenes and tumor suppressor genes that participate in its genesis and progression. To address this issue, several protooncogenes, including K-ras, N-ras, erbB-2, erbB-3,c-myc, c-fos, c-jun were examined. Also analyzed was the expression of the growth factors TGF-alpha, EGF, and insulin as well as the EGF receptor (EGF-R), p53 and the putative anti-metastasis gene nm23-H1. These were examined in malignant insulinomas, benign insulinomas, pancreatic B cell hyperplasias and in normal endocrine pancreas. Normal endocrine pancreas showed moderate immunoreaction for c-myc and a strong reaction for insulin. All other parameters were negative. Benign pancreatic B cell hyperplasias were slightly or moderately positive for N-ras and TGF-alpha, and were weakly positive for EGF-R. They were strongly positive for c-myc and insulin. In malignant insulinomas there was strong immunoreaction for c-myc, TGF-alpha, N-ras, K-ras and p53. Insulin reaction was moderate or strong. Molecular genetic studies have been performed for the presence of activating point mutations in codon 12 of the c-K-ras oncogene. Mutations were detected using primer-mediated, mutant-enriched, polymerase chain reaction-restriction fragment length polymorphism analysis and were further characterized by allele-specific oligonucleotide hybridization. Four out of six patients with malignant insulinoma and two out of eight patients with benign insulinoma harbored K-ras point mutations at codon 12. All patients with mutated K-ras oncogene also had elevated levels of p53 protein as well as c-myc and TGF-alpha. In one extremely malignant case we found concomitant mutation at codon 12 of K-ras and codon 61 of the N-ras gene. Our data are consistent with the idea that malignant progression is accompanied by the progressive accumulation of multiple genetic lesions and suggest that activation of myc, TGF-alpha and ras genes may be early events in the development of insulinoma.
Insights
Malignant insulinoma progression involves accumulating genetic changes, with activated myc, TGF-alpha, and ras genes potentially being early drivers. K-ras mutations are found in both benign and malignant forms, indicating their role in insulinoma development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Malignant insulinoma is a rare cancer with a poor prognosis.
- The etiology and genetic underpinnings of malignant insulinoma are poorly understood.
Purpose of the Study:
- To investigate the expression of oncogenes, growth factors, and tumor suppressor genes in insulinomas.
- To identify genetic alterations associated with malignant transformation and progression in insulinoma.
Main Methods:
- Immunohistochemistry was used to analyze protein expression of various genes (K-ras, N-ras, c-myc, TGF-alpha, p53, etc.) in normal pancreas, benign hyperplasia, and malignant insulinomas.
- Polymerase chain reaction-restriction fragment length polymorphism and allele-specific oligonucleotide hybridization were employed to detect K-ras and N-ras gene mutations.
Main Results:
- Malignant insulinomas showed strong expression of c-myc, TGF-alpha, N-ras, K-ras, and p53.
- K-ras point mutations at codon 12 were detected in 4/6 malignant and 2/8 benign insulinomas.
- Patients with K-ras mutations often had elevated p53, c-myc, and TGF-alpha levels.
Conclusions:
- Malignant progression of insulinoma is associated with the accumulation of multiple genetic lesions.
- Activation of myc, TGF-alpha, and ras genes may represent early events in insulinoma development.